Stockscreener 앱 받기
14.66
1.35%
-0.20
시간 외 거래:
14.49
-0.17
-1.16%
Promis Neurosciences Inc 주식(PMN)의 최신 뉴스
ProMIS Neurosciences (PMN) Q2 2026 Update Highlights Strong Cash Position Amid High Valuation - GuruFocus
ProMIS Neurosciences (PMN) Holds Near $14.86 as Traders Eye Key Resistance at $15.60Call Wall - dars.gov.et
PMN Maintained by Guggenheim -- Price Target Raised to $100 - GuruFocus
Guggenheim Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Raises Target Price to $100 - Moomoo
ProMIS Neurosciences Inc. Stock 12‑Month Price Target Raised to $43.64, Implies 195% Upside - TradingView
Promis Neurosciences (NASDAQ:PMN) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat
Chardan Capital Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Raises Target Price to $33 - Moomoo
ProMIS Neurosciences Inc (PMN) (Q2 2026) Earnings Call Highlight - GuruFocus
Promis Neurosciences Q2 Earnings Call Highlights - MarketBeat
PROMIS NEUROSCIENCES ($PMN) Releases Q2 2026 Earnings - Quiver Quantitative
Earnings call transcript: ProMIS Neurosciences posts strong cash position in Q2 2026 - Investing.com Canada
PMN: Interim phase I-B data for PMN310 showed no ARIA-E and strong biomarker signals, with cash runway through 2027 - TradingView
ProMIS Neurosciences Q2 Results: Cash Runway Extends To 2027 - scanx.trade
Promis Neurosciences (NASDAQ:PMN) Issues Quarterly Earnings Results, Beats Estimates By $0.10 EPS - MarketBeat
ProMIS Neurosciences Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
ProMIS Neurosciences Inc. Q2 2026: Net loss $(11.73)M, Diluted EPS $(1.28) — 10-Q Summary - TradingView
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights - The Manila Times
ProMIS Neurosciences (PMN) extends cash runway with $70.1M PIPE amid higher R&D - Stock Titan
ProMIS Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
ProMIS Neurosciences Inc expected to post a loss of $1.38 a shareEarnings Preview - TradingView
ProMIS Neurosciences Inc (PMN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Insider at ProMIS Neurosciences (PMN) buys 2,280 common shares - Stock Titan
ProMIS Neurosciences Inc (PMN) Stock News Today - TradingKey
Promis Neurosciences (NASDAQ:PMN) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Promis Neurosciences (PMN) Projected to Post Earnings on Thursday - MarketBeat
Janus Henderson Group PLC Acquires New Position in Promis Neurosciences $PMN - MarketBeat
ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026 - The Manila Times
ProMIS schedules 4:30 p.m. webcast for Aug. 13 update - Stock Titan
ADAR1 Capital Management LLC Buys Shares of 95,350 Promis Neurosciences $PMN - MarketBeat
Promis Neurosciences (NASDAQ:PMN) Upgraded at Chardan Capital - MarketBeat
PMN Maintains Buy Rating by Chardan Capital -- Price Target Rais - GuruFocus
Chardan raises ProMIS Neurosciences stock price target on trial data By Investing.com - Investing.com Canada
Chardan Adjusts Price Target on ProMIS Neurosciences to $33 From $20, Maintains Buy Rating - marketscreener.com
ProMIS Neurosciences (PMN) Reports Promising Interim Biomarker D - GuruFocus
Why is ProMIS Neurosciences stock surging today? By Investing.com - Investing.com Canada
ProMIS Neurosciences (PMN) Surges 21.3% Pre-Market Ahead of Earn - GuruFocus
ProMIS Neurosciences Says PMN310 Alzheimer Drug Shows Positive Interim Safety, Biomarker Data - marketscreener.com
ProMIS Neurosciences (PMN) Reports Promising Interim Biomarker Data Amid High Valuation Expectations - GuruFocus
ProMIS Neurosciences Inc. Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in PRECISE-AD Phase 1b Alzheimer?s Disease Trial - marketscreener.com
ProMIS Neurosciences stock jumps on trial safety data By Investing.com - Investing.com South Africa
ProMIS Neurosciences stock jumps on trial safety data - Investing.com
ProMIS Reports Positive Interim PMN310 Alzheimer’s Trial Data - TipRanks
ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial - The Manila Times
ProMIS Neurosciences Reports Positive 6-Month Interim Safety and Biomarker Results for PMN310 in Phase 1b Alzheimer's Trial - Moomoo
ProMIS Neurosciences Reports Positive 6-Month Interim Safety and Biomarker Results for PMN310 in Phase 1b Alzheimer’s Trial - Quiver Quantitative
ProMIS Neurosciences (Nasdaq: PMN) reports positive six-month PMN310 Alzheimer’s trial data - Stock Titan
ProMIS Neurosciences Inc (PMN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ProMIS Neurosciences PMN310 shows early Alzheimer's promise - scanx.trade
ProMIS Neurosciences Inc (PMN) Income Statement - TradingKey
ProMIS Neurosciences to present interim Alzheimer’s trial data on PMN310 - TipRanks
ProMIS to host webinar on Alzheimer’s trial interim data - Investing.com
ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease - marketscreener.com
Two Alzheimer’s researchers join ProMIS webinar on blinded trial data - Stock Titan
PMN Initiated Coverage by Chardan Capital -- Rating Set to Buy - GuruFocus
PMN|ProMIS Neurosciences Inc|Price:13.720|Chg%:-1.200 - TradingKey
Chardan Initiates ProMIS Neurosciences at Buy With $20 Price Target - moomoo.com
ProMIS Neurosciences Inc (PMN) Balance Sheet - TradingKey
Chardan initiates ProMIS Neurosciences stock with buy rating By Investing.com - Investing.com Canada
Chardan Capital Initiates ProMIS Neurosciences(PMN.US) With Buy Rating, Announces Target Price $20 - moomoo.com
PMN|ProMIS Neurosciences Inc|Price:12.200|Chg%:-0.410 - TradingKey
ProMIS Neurosciences Inc (PMN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ProMIS Neurosciences Inc (PMN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ProMIS Neurosciences Inc (PMN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ProMIS Neurosciences Inc (PMN) Institutional Confidence - TradingKey
ProMIS Neurosciences Inc (PMN) Cash Flow - TradingKey
1.80%
1.77%
자본화:
|
볼륨(24시간):